First-in-Human trial launches for 'Living Drug' aiming to tame severe lupus
NCT ID NCT07358988
Summary
This is an early-stage safety study testing a new type of cell therapy called KN5501 for adults with moderate to severe, hard-to-treat systemic lupus erythematosus (SLE). Researchers will give patients an infusion of specially engineered immune cells designed to target and reduce harmful B cells, which are thought to drive lupus. The main goals are to see if the treatment is safe, determine the right dose, and check for early signs that it might lower lupus disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bengbu Medical College First Affiliated Hospital
Bengbu, Anhui, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Changhai Hospital of Shanghai
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.